WO2002083674A3 - Imidazotriazinonhaltige zusammensetzungen zur nasalen applikation - Google Patents

Imidazotriazinonhaltige zusammensetzungen zur nasalen applikation Download PDF

Info

Publication number
WO2002083674A3
WO2002083674A3 PCT/EP2002/003663 EP0203663W WO02083674A3 WO 2002083674 A3 WO2002083674 A3 WO 2002083674A3 EP 0203663 W EP0203663 W EP 0203663W WO 02083674 A3 WO02083674 A3 WO 02083674A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions containing
imidazotriazinone
nasal application
nasal
application
Prior art date
Application number
PCT/EP2002/003663
Other languages
English (en)
French (fr)
Other versions
WO2002083674A2 (de
Inventor
Peter Serno
Andreas Ohm
Wolfgang Barth
Richard-Josef Bauer
Hans-Martin Siefert
Dieter Zimmer
Original Assignee
Bayer Ag
Peter Serno
Andreas Ohm
Wolfgang Barth
Richard-Josef Bauer
Hans-Martin Siefert
Dieter Zimmer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to EEP200300501A priority Critical patent/EE200300501A/xx
Priority to CA002443639A priority patent/CA2443639A1/en
Priority to PL02363033A priority patent/PL363033A1/xx
Priority to EP02732548A priority patent/EP1381368A2/de
Priority to IL15825502A priority patent/IL158255A0/xx
Priority to KR10-2003-7013280A priority patent/KR20030087072A/ko
Priority to HU0303877A priority patent/HUP0303877A3/hu
Priority to SK1268-2003A priority patent/SK12682003A3/sk
Application filed by Bayer Ag, Peter Serno, Andreas Ohm, Wolfgang Barth, Richard-Josef Bauer, Hans-Martin Siefert, Dieter Zimmer filed Critical Bayer Ag
Priority to MXPA03009314A priority patent/MXPA03009314A/es
Priority to BR0208813-4A priority patent/BR0208813A/pt
Priority to JP2002581429A priority patent/JP2004525968A/ja
Publication of WO2002083674A2 publication Critical patent/WO2002083674A2/de
Publication of WO2002083674A3 publication Critical patent/WO2002083674A3/de
Priority to NO20034556A priority patent/NO20034556L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Otolaryngology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Anesthesiology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Die vorliegende Erfindung betrifft Imidiazotriazinonhaltige Zusammensetzungen zur nasalen Applikation, welche neben dem cGMP PDE-Inhibitor eine geringe Menge eines Lokalanästhetikums enthalten.
PCT/EP2002/003663 2001-04-12 2002-04-03 Imidazotriazinonhaltige zusammensetzungen zur nasalen applikation WO2002083674A2 (de)

Priority Applications (12)

Application Number Priority Date Filing Date Title
HU0303877A HUP0303877A3 (en) 2001-04-12 2002-04-03 Compositions containing imidazotriazinone for nasal application
PL02363033A PL363033A1 (en) 2001-04-12 2002-04-03 Compositions containing imidazotriazinone for nasal application
EP02732548A EP1381368A2 (de) 2001-04-12 2002-04-03 Imidazotriazinonhaltige zusammensetzungen zur nasalen applikation
IL15825502A IL158255A0 (en) 2001-04-12 2002-04-03 Compositions containing imidazotriazinone for nasal application
KR10-2003-7013280A KR20030087072A (ko) 2001-04-12 2002-04-03 비측 투여를 위한 이미다조트리아지논 함유 조성물
EEP200300501A EE200300501A (et) 2001-04-12 2002-04-03 Ninna manustatavad imidasotriasinooni sisaldavad kompositsioonid
SK1268-2003A SK12682003A3 (sk) 2001-04-12 2002-04-03 Prípravky obsahujúce imidazotriazinón na nazálnu aplikáciu
CA002443639A CA2443639A1 (en) 2001-04-12 2002-04-03 Compositions containing imidazotriazinone for nasal application
MXPA03009314A MXPA03009314A (es) 2001-04-12 2002-04-03 Composiciones que contienen imidazotriazinona para administracion nasal.
BR0208813-4A BR0208813A (pt) 2001-04-12 2002-04-03 Composições contendo imidazotriazinona para a aplicação nasal
JP2002581429A JP2004525968A (ja) 2001-04-12 2002-04-03 鼻適用のためのイミダゾトリアジノン含有の組成物
NO20034556A NO20034556L (no) 2001-04-12 2003-10-10 Imidazotriazinon-holdige sammensetninger for nasal administrering

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10118306.2 2001-04-12
DE10118306A DE10118306A1 (de) 2001-04-12 2001-04-12 Imidazotriazinonhaltige Zusammensetzungen zur nasalen Applikation

Publications (2)

Publication Number Publication Date
WO2002083674A2 WO2002083674A2 (de) 2002-10-24
WO2002083674A3 true WO2002083674A3 (de) 2003-01-09

Family

ID=7681379

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2002/003663 WO2002083674A2 (de) 2001-04-12 2002-04-03 Imidazotriazinonhaltige zusammensetzungen zur nasalen applikation

Country Status (25)

Country Link
US (2) US6740306B2 (de)
EP (1) EP1381368A2 (de)
JP (1) JP2004525968A (de)
KR (1) KR20030087072A (de)
CN (1) CN1537004A (de)
AR (1) AR035821A1 (de)
BG (1) BG108245A (de)
BR (1) BR0208813A (de)
CA (1) CA2443639A1 (de)
CZ (1) CZ20032752A3 (de)
DE (1) DE10118306A1 (de)
DO (1) DOP2002000373A (de)
EC (1) ECSP034795A (de)
EE (1) EE200300501A (de)
GT (1) GT200200070A (de)
HU (1) HUP0303877A3 (de)
IL (1) IL158255A0 (de)
MX (1) MXPA03009314A (de)
NO (1) NO20034556L (de)
PE (1) PE20021035A1 (de)
PL (1) PL363033A1 (de)
RU (1) RU2003133143A (de)
SK (1) SK12682003A3 (de)
UY (1) UY27256A1 (de)
WO (1) WO2002083674A2 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2449163C (en) * 2001-05-09 2010-07-13 Bayer Healthcare Ag New use of 2-phenyl-substituted imidazotriazinones
DE102004023069A1 (de) * 2004-05-11 2005-12-08 Bayer Healthcare Ag Neue Darreichungsformen des PDE 5-Inhibitors Vardenafil
ZA200704869B (en) * 2004-12-23 2009-02-25 Roxro Pharma Inc Therapeutic compositions for intranasal administration of ketorolac
DE102005001989A1 (de) * 2005-01-15 2006-07-20 Bayer Healthcare Ag Intravenöse Formulierungen von PDE-Inhibitoren
DE102005009240A1 (de) * 2005-03-01 2006-09-07 Bayer Healthcare Ag Arzneiformen mit verbesserten pharmakokinetischen Eigenschaften
DE102005009241A1 (de) * 2005-03-01 2006-09-07 Bayer Healthcare Ag Arzneiformen mit kontrollierter Bioverfügbarkeit
MX2008000087A (es) * 2005-06-23 2008-03-18 Schering Corp Formulaciones orales rapidamente absorbentes de inhibidores de la fosfodiesterasa 5.
KR20080056250A (ko) * 2005-09-29 2008-06-20 바이엘 헬스케어 아게 비뇨기 장애의 치료를 위한 ｐｄｅ 억제제 및 이들의 조합
CN101711153A (zh) * 2007-06-13 2010-05-19 拜耳先灵制药股份公司 用于治疗听觉损伤的pde抑制剂
AU2009257385A1 (en) * 2008-06-13 2009-12-17 Roxro Pharma, Inc. Pharmaceutical formulation of ketorolac for intranasal administration
US8277781B2 (en) * 2009-03-13 2012-10-02 Luitpold Pharmaceuticals, Inc. Device for intranasal administration
US8551454B2 (en) * 2009-03-13 2013-10-08 Luitpold Pharmaceuticals, Inc. Device for intranasal administration
WO2017168174A1 (en) 2016-04-02 2017-10-05 N4 Pharma Uk Limited New pharmaceutical forms of sildenafil
WO2020006606A1 (en) * 2018-07-05 2020-01-09 Helium 3 Resources Pty Ltd A pharmaceutical composition and method of use of same
SE542968C2 (en) * 2018-10-26 2020-09-22 Lindahl Anders Treatment of osteoarthritis
BR112022024098A2 (pt) * 2020-05-26 2023-02-07 Strategic Drug Solutions Inc Formulações e métodos para tratar a disfunção erétil

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4602099A (en) * 1973-04-02 1986-07-22 Merrell Dow Pharmaceuticals Inc. Antirhinovirus agents
GB2315673A (en) * 1996-08-01 1998-02-11 Merck & Co Inc Treatment of migraine
EP0967214A1 (de) * 1998-06-22 1999-12-29 Pfizer Limited Intranasale Zubereitungen zur Behandlung sexueller Störungen
WO2000000199A1 (en) * 1998-06-26 2000-01-06 Nastech Pharmaceutical Company, Inc. Nasal delivery of sildenafil citrate
EP0992240A1 (de) * 1997-05-29 2000-04-12 Mochida Pharmaceutical Co., Ltd. Therapeutisches mittel bei erektionsstoerungen

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9013750D0 (en) 1990-06-20 1990-08-08 Pfizer Ltd Therapeutic agents
GB9301192D0 (en) 1993-06-09 1993-06-09 Trott Francis W Flower shaped mechanised table
GB9514465D0 (en) 1995-07-14 1995-09-13 Glaxo Lab Sa Chemical compounds
GB9514473D0 (en) 1995-07-14 1995-09-13 Glaxo Lab Sa Chemical compounds
EP0985671B1 (de) 1996-05-31 2003-04-02 Mochida Pharmaceutical Co., Ltd. PYRIDOCARBAZOL DERIVATE DIE EINEN cGMP-PDE INHIBILIERENDEN EFFEKT HABEN
AU9214498A (en) 1997-09-23 1999-04-12 Eli Lilly And Company Treatment of attention-deficit/hyperactivity disorder
EP2295436A1 (de) 1997-11-12 2011-03-16 Bayer Schering Pharma AG 2-Phenyl-substituierte Imidazotriazinone als Phosphodiesterase V Inhibitoren
HUP0104676A3 (en) * 1998-12-14 2005-12-28 Cellegy Pharmaceuticals Inc So Compositions for the treatment of anorectal disorders and their use

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4602099A (en) * 1973-04-02 1986-07-22 Merrell Dow Pharmaceuticals Inc. Antirhinovirus agents
GB2315673A (en) * 1996-08-01 1998-02-11 Merck & Co Inc Treatment of migraine
EP0992240A1 (de) * 1997-05-29 2000-04-12 Mochida Pharmaceutical Co., Ltd. Therapeutisches mittel bei erektionsstoerungen
EP0967214A1 (de) * 1998-06-22 1999-12-29 Pfizer Limited Intranasale Zubereitungen zur Behandlung sexueller Störungen
WO2000000199A1 (en) * 1998-06-26 2000-01-06 Nastech Pharmaceutical Company, Inc. Nasal delivery of sildenafil citrate

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SOMMER FRANK ET AL: "Vardenafil Bayer Yakuhin.", CURRENT OPINION IN INVESTIGATIONAL DRUGS (LONDON, ENGLAND: 2000) ENGLAND APR 2002, vol. 3, no. 4, April 2002 (2002-04-01), pages 607 - 613, XP001119414, ISSN: 1472-4472 *

Also Published As

Publication number Publication date
RU2003133143A (ru) 2005-04-10
US20030022894A1 (en) 2003-01-30
BG108245A (en) 2005-01-31
IL158255A0 (en) 2004-05-12
NO20034556L (no) 2003-12-10
WO2002083674A2 (de) 2002-10-24
PE20021035A1 (es) 2002-11-29
ECSP034795A (es) 2003-12-01
PL363033A1 (en) 2004-11-15
CA2443639A1 (en) 2002-10-24
US20040248891A1 (en) 2004-12-09
CN1537004A (zh) 2004-10-13
DE10118306A1 (de) 2002-10-17
DOP2002000373A (es) 2002-11-30
NO20034556D0 (no) 2003-10-10
HUP0303877A2 (hu) 2004-03-29
MXPA03009314A (es) 2004-03-10
KR20030087072A (ko) 2003-11-12
HUP0303877A3 (en) 2005-05-30
EE200300501A (et) 2003-12-15
UY27256A1 (es) 2002-11-29
EP1381368A2 (de) 2004-01-21
GT200200070A (es) 2003-01-31
CZ20032752A3 (cs) 2004-01-14
US6740306B2 (en) 2004-05-25
JP2004525968A (ja) 2004-08-26
SK12682003A3 (sk) 2004-03-02
BR0208813A (pt) 2004-03-09
AR035821A1 (es) 2004-07-14

Similar Documents

Publication Publication Date Title
WO2002083674A3 (de) Imidazotriazinonhaltige zusammensetzungen zur nasalen applikation
HUP0303886A3 (en) New film coating composition for coating of pharmaceutical compositions
HK1071886A1 (en) Novel compounds and compositions as cathepsin inhibitors
WO2005004842A3 (en) Formulations for coated microprojections containing non-volatile counterions
GB2381450B (en) Compositions for administration of natural or synthetic cannabinoids by vaporisation
AU2002253882A1 (en) Coating compositions for modifying surfaces
AU2002300709A1 (en) Corrosion inhibiting compositions
EP1466610A4 (de) Medizinische zusammensetzungen zur aufnahme über die nase
AP2001002204A0 (en) Pyrazole derivatives.
AU2002350191A8 (en) Substituted heteroarylalkanoic acids and their use as aldose reductase inhibitors
AU2002357671A1 (en) Compositions for aqueous delivery of self-emulsifying fluorinated alkoxysilanes
AU2002343661A1 (en) Modified prostaglandin compounds and analogs thereof, compositions containing the same useful for the teatment of cancer
WO2005110421A3 (de) Aerosolformulierung für die inhalation von betaagonisten
PL367128A1 (en) Chemical compounds and pharmaceutical compositions as cathepsin s inhibitors
BR0307595A (pt) Uso de inibidores de pde5 tal como sildenafil no tratamento de sìndrome de ovário policìstico
AU2002356646A1 (en) Pharmaceutical compositions for the pulmonary delivery of aztreonam
MXPA03005980A (es) Composiciones para administracion nasal de insulina.
AU2002346143A1 (en) Compositions for nasal administration of insulin
WO2003022844A3 (en) Synthesis of epothilones intermediates thereto and analogues thereof
EP1350522A4 (de) Topische anästesiezusammensetzungen
WO2002083108A3 (de) Zusammensetzungen enthaltend cgmp-pde-inhibitoren und lokalanästhetika zur nasalen applikation
IL140990A0 (en) Thick film compositions containing pyrochlore-related compounds
WO2006005017A3 (en) Oral composition comprising carbamylating agent
WO2005105799A8 (en) Dialkoxy-imidazopyridines derivatives
AU4853101A (en) Respiratory compositions

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2002732548

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 158255

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2002304803

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 200307849

Country of ref document: ZA

ENP Entry into the national phase

Ref document number: 10824502

Country of ref document: BG

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 528768

Country of ref document: NZ

Ref document number: 2443639

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 12682003

Country of ref document: SK

Ref document number: PA/a/2003/009314

Country of ref document: MX

Ref document number: PV2003-2752

Country of ref document: CZ

Ref document number: 1-2003-501014

Country of ref document: PH

Ref document number: 1020037013280

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 958/MUMNP/2003

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2002581429

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 028114574

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: PV2003-2752

Country of ref document: CZ

WWP Wipo information: published in national office

Ref document number: 2002732548

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWR Wipo information: refused in national office

Ref document number: PV2003-2752

Country of ref document: CZ